Navigation Links
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/2/2009

SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 11th Annual BIO CEO and Investor Conference on Monday, February 9, 2009 at 11:00 a.m. EST (8:00 a.m. PST). The conference is being held at the Waldorf-Astoria Hotel in New York.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and an update on its clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

Additionally, Dr. Worland will participate as a panelist on the Infectious Disease panel, which will address the changing HCV landscape, the current role of direct acting anti-virals in HCV therapy, and the future of HCV combination therapy at the conference on Monday, February 9 at 1:45 p.m.

The corporate presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through February 23, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended September 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
4. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
5. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
6. Major Shareholders Criticize Enzon Pharmaceuticals Management Team in Open Letter
7. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
8. ePharmaceuticals™ Announces the Launch of epharmcomply.com
9. Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines
10. Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
11. Amylin Pharmaceuticals Reports 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Erlanger Agency ... the greater Columbus, OH area. The latest campaign focuses on the fight against breast ... Donations are now being accepted here . , Carmen is a loving single ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the ... and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the collaboration, ... facilities as a way to accommodate a more certain time frame for donor families ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet Lake, ... and dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry ... donating their time and skills to help hundreds of uninsured and underinsured people receive ...
(Date:2/12/2016)... New York, NY (PRWEB) , ... February 12, ... ... latest edition of “Revolutionizing Cancer Care.” , The print component of ... in Chicago, Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Strategies for Health Plans and PBMs,” an upcoming Feb. 24 webinar that will ... access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016 (Kanadische ... http://www.sedar.com ) und der Website ... --> http://www.sedar.com ) und ... abrufbar.    --> Telesta ... Konzernabschluss des zweiten Quartals und die ...
(Date:2/12/2016)... HOUSTON , Feb. 12, 2016  Memorial Hermann ... center Dwight Howard to bring a one-of-a-kind ... Hospital . Using cutting-edge technologies such as 360-degree video ... kids both virtually, then literally – giving the patients ... – and it was all caught on video ...
(Date:2/12/2016)... INDIANAPOLIS , Feb. 12, 2016  Eli Lilly and ... High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent ... in the UK, France , ... instructions to dilute the product only with dextrose solution.  ... of 2015, the UK Court of Appeal held that Lilly,s ...
Breaking Medicine Technology: